Markets & Stocks

Stock quotes, market indicators and the latest market news.

Market Summary Market News Stock Quotes Market Movers

Connect Biopharma Holdings Limited - Ordinary Shares (NQ:CNTB)

0.9797 -0.1203 (-10.94%)

Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist

Price and Volume

Volume	7,920,685
Open	1.115
Bid (Size)	0.9702 (3,000)
Ask (Size)	0.9788 (1,500)
Prev. Close	1.100
Today's Range	0.9433 - 1.120
52wk Range	0.9800 - 3.820
Shares Outstanding	55,041,247
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Top movers analysis one hour before the close of the markets on 2026-09-30: top gainers and losers in today's session. ↗

September 30, 2026

Via Chartmill

Discover the most active stocks in Wednesday's session. ↗

September 30, 2026

Via Chartmill

Performance

YTD	-61.1%	-61.1%
1 Month	-55.5%	-55.5%
3 Month	-59.0%	-59.0%
6 Month	-64.0%	-64.0%
1 Year	-35.1%	-35.1%

More News

Let's take a look at the stocks that are in motion in today's session. ↗

September 30, 2026

Via Chartmill

Which stocks are gapping on Wednesday? ↗

September 30, 2026

Via Chartmill

Wednesday's pre-market session: top gainers and losers ↗

September 30, 2026

Via Chartmill

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation

September 30, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

September 15, 2026

Via Chartmill

Keep an eye on the top gainers and losers in Tuesday's session. ↗

September 15, 2026

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

September 15, 2026

Via Chartmill

What's going on in today's pre-market session ↗

September 15, 2026

Via Chartmill

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation

September 15, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

These stocks are moving in today's after hours session ↗

September 03, 2026

Via Chartmill

Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 03, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update

August 12, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

June 17, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma Touts Rademikibart’s Edge as SEABREEZE Data Looms in 2026 ↗

May 22, 2026

Via MarketBeat

Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

May 12, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis

April 23, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms

April 07, 2026

Via ACCESS Newswire

Wondering what's happening in today's after-hours session? ↗

April 01, 2026

Via Chartmill

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

March 31, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma Announces $20.2 Million Private Placement Financing

March 30, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

March 30, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD

March 30, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Frequently Asked Questions

Is Connect Biopharma Holdings Limited - Ordinary Shares publicly traded?

Yes, Connect Biopharma Holdings Limited - Ordinary Shares is publicly traded.

What exchange does Connect Biopharma Holdings Limited - Ordinary Shares trade on?

Connect Biopharma Holdings Limited - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Connect Biopharma Holdings Limited - Ordinary Shares?

The ticker symbol for Connect Biopharma Holdings Limited - Ordinary Shares is CNTB on the Nasdaq Stock Market

What is the current price of Connect Biopharma Holdings Limited - Ordinary Shares?

The current price of Connect Biopharma Holdings Limited - Ordinary Shares is 0.9797

When was Connect Biopharma Holdings Limited - Ordinary Shares last traded?

The last trade of Connect Biopharma Holdings Limited - Ordinary Shares was at 10/01/26 04:00 PM ET

What is the market capitalization of Connect Biopharma Holdings Limited - Ordinary Shares?

The market capitalization of Connect Biopharma Holdings Limited - Ordinary Shares is 53.92M

How many shares of Connect Biopharma Holdings Limited - Ordinary Shares are outstanding?

Connect Biopharma Holdings Limited - Ordinary Shares has 54M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.